Activation of a p53-mediated apoptotic pathway in quiescent lymphocytes after the inhibition of DNA repair by fludarabine

Clinical Cancer Research

Volumn 9, Issue 8, 2003, Pages 3204-3212

  Rao, V Ashutosh ^b   Plunkett, William ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APHIDICOLIN; CASPASE 3; CASPASE 8; FAS ANTIGEN; FAS LIGAND; FLUDARABINE; LIGAND; MESSENGER RNA; NEUTRALIZING ANTIBODY; NUCLEOTIDE; PLASMA PROTEIN; PROTEIN P53; SERINE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA REPAIR; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INCUBATION TIME; LYMPHOCYTE; METABOLITE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; ULTRAVIOLET IRRADIATION;

ANTIGENS, CD95; APHIDICOLIN; APOPTOSIS; CASPASE 3; CASPASE 8; CASPASES; CELL SURVIVAL; CELLS, CULTURED; DNA REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; HUMANS; IMMUNOBLOTTING; LYMPHOCYTES; MEMBRANE GLYCOPROTEINS; PHOSPHORYLATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERINE; SIGNAL TRANSDUCTION; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; ULTRAVIOLET RAYS; VIDARABINE;

EID: 0042024916     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Keating, M. J., O'Brien, S., Lerner, S., Koller, C., Beran, M., Robertson, L. E., Freireich, E. J., Estey, E., and Kantarjian, H. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood, 92: 1165-1171, 1998.
2. McLaughlin, P., Hagemeister, F. B., Romaguera, J. E., Sarris, A. H., Pate, O., Younes, A., Swan, F., Keating, M., and Cabanillas, F. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J. Clin. Oncol., 14: 1262-1268, 1996.
3. Huang, P., and Plunkett, W. Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event. Cancer Chemother. Pharmacol., 36: 181-188, 1995.
4. Spriggs, D., Robbins, G., Mitchell, T., and Kufe, D. Incorporation of 9-β-D-arabinofuranosyl-2-fluoroadenine into HL-60 cellular RNA and DNA. Biochem. Pharmacol., 15: 247-252, 1986.
5. Huang, P., Chubb, S., and Plunkett, W. Termination of DNA synthesis by 9-β-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J. Biol. Chem., 265: 16617-25, 1990.
6. Kamiya, K., Huang, P., and Plunkett, W. Inhibition of the 3′→5′ exonuclease of human DNA polymerase epsilon by fludarabine-terminated DNA. J. Biol. Chem., 271: 19428-35, 1996.
7. Tseng, W. C., Derse, D., Cheng, Y. C., Brockman, R. W., and Bennett, L. L., Jr. In vitro biological activity of 9-β-D-arabinofuranosyl-2-fluoradenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells. Mol. Pharmacol., 21: 474-477, 1982.
8. Kufe, D. W., Weichselbaum, R., Egan, E. M., Dahlberg, W., and Fram, R. J. Lethal effects of 1-β-D-arabinofuranosylcytosine incorporation into deoxyribonucleic acid during ultraviolet repair. Mol. Pharmacol., 25: 322-326, 1984.
9. Sandoval, A., Consoli, U., and Plunkett, W. Fludarabine-mediated inhibition of nucleotide excision repair induces apoptosis in quiescent human lymphocytes. Clin. Cancer Res., 2: 1731-1741, 1996.
10. Yamauchi, T., Nowak, B. J., Keating, M. J., and Plunkett, W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin. Cancer Res., 7: 3580-3589, 2001.
11. Abraham, R. T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev., 15: 2177-2196, 2001.
12. Shiloh, Y. ATM and ATR: networking cellular responses to DNA damage. Curr. Opin. Genet. Dev., 11: 71-77, 2001.
13. Scully, R., Chen, J., Ochs, R. L., Keegan, K., Hoekstra, M., Feunteun, J., and Livingston, D. M. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell, 90: 425-435, 1997.
14. Tibbetts, R. S., Cortez, D., Brumbaugh, K. M., Scully, R., Livingston, D., Elledge, S. J., and Abraham, R. T. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev., 14: 2989-3002, 2000.
15. Chen, J. Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage. Cancer Res., 60: 5037-5039, 2000.
16. Huang, Y., Yuan, Z. M., Ishiko, T., Nakada, S., Utsugisawa, T., Kato, T., Kharbanda, S., and Kufe, D. W. Pro-apoptotic effect of the c-Abl tyrosine kinase in the cellular response to 1-β-D-arabinofuranosylcytosine. Oncogene, 15: 1947-1952, 1997.
17. Yuan, Z. M., Huang, Y., Fan, M. M., Sawyers, C., Kharbanda, S., and Kufe, D. Genotoxic drugs induce interaction of the c-Abl tyrosine kinase and the tumor suppressor protein p53. J. Biol. Chem., 271: 26457-60, 1996.
18. Herr, I., and Debatin, K. M. Cellular stress response and apoptosis in cancer therapy. Blood, 98: 2603-2614, 2001.
19. Raina, D., Mishra, N., Kumar, S., Kharbanda, S., Saxena, S., and Kufe, D. Inhibition of c-Abl with STI571 attenuates stress-activated protein kinase activation and apoptosis in the cellular response to 1-β-D-arabinofuranosylcytosine. Mol. Pharmacol., 61: 1489-1495, 2002.
20. Gunji, H., Kharbanda, S., and Kufe, D. Induction of internucleosomal DNA fragmentation in human myeloid leukemia cells by 1-β-D-arabinofuranosylcytosine. Cancer Res., 51: 741-743, 1991.
21. Ray, S., Ponnathpur, V., Huang, Y., Tang, C., Mahoney, M. E., Ibrado, A. M., Bullock, G., and Bhalla, K. 1-β-D-Arabinofuranosylcytosine-, mitoxantrone-, and paclitaxel-induced apoptosis in HL-60 cells: improved method for detection of internucleosomal DNA fragmentation. Cancer Chemother. Pharmacol., 34: 365-371, 1994.
22. Friesen, C., Fulda, S., and Debatin, K. M. Cytotoxic drugs and the CD95 pathway. Leukemia (Baltimore), 13: 1854-1858, 1999.
23. Giaccia, A. J., and Kastan, M. B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev., 12: 2973-2983, 1998.
24. Siliciano, J. D., Canman, C. E., Taya, Y., Sakaguchi, K., Appella, E., and Kastan, M. B. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev., 11: 3471-3481, 1997.
25. Muller, M., Scaffidi, C. A., Galle, P. R., Stremmel, W., and Krammer, P. H. The role of p53 and the CD95 (APO-1/Fas) death system in chemotherapy-induced apoptosis. Eur. Cytokine Netw., 9: 685-686, 1998.
26. Canman, C. E., Lim, D. S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., and Siliciano, J. D. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science (Wash. DC), 281: 1677-1679, 1998.
27. Lakin, N. D., and Jackson, S. P. Regulation of p53 in response to DNA damage. Oncogene, 18: 7644-7655, 1999.
28. Muller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., and Galle, P. R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Investig., 99: 403-413, 1997.
29. Muller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., and Krammer, P. H. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med., 188: 2033-2045, 1998.
30. Kobayashi, T., Ruan, S., Jabbur, J. R., Consoli, U., Clodi, K., Shiku, H., Owen-Schaub, L. B., Andreeff, M., Reed, J. C., and Zhang, W. Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment. Cell Death Differ., 5: 584-591, 1998.
31. Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W. W., Kruzel, E., et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol., 15: 3032-3040, 1995.
32. Fukazawa, T., Fujiwara, T., Morimoto, Y., Shao, J., Nishizaki, M., Kadowaki, Y., Hizuta, A., Owen-Schaub, L. B., Roth, J. A., and Tanaka, N. Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells. Oncogene, 18: 2189-2199, 1999.
33. Pinkoski, M. J., and Green, D. R. Fas ligand, death gene. Cell Death Differ., 6: 1174-1181, 1999.
34. Zimmermann, K. C., Bonzon, C., and Green, D. R. The machinery of programmed cell death. Pharmacol. Ther., 92: 57-70, 2001.
35. Budihardjo, I., Oliver, H., Lutter, M., Luo, X., and Wang, X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol., 15: 269-290, 1999.
36. Friesen, C., Herr, I., Krammer, P. H., and Debatin, K. M. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat. Med., 2: 574-577, 1996.
37. Sheaff, R., Ilsley, D., and Kuchta, R. Mechanism of DNA polymerase inhibition by aphidicolin. Biochemistry, 30: 8590-8597, 1991.
38. Li, L., Liu, X., Glassman, A. B., Keating, M. J., Stros, M., Plunkett, W., and Yang, L. Y. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res., 57: 1487-1494, 1997.
39. Wood, R. D. DNA repair in eukaryotes. Annu. Rev. Biochem., 65: 135-167, 1996.
40. Sancar, A. DNA excision repair. Annu. Rev. Biochem., 65: 43-81, 1996.
41. Moses, R. E. DNA damage processing defects and disease. Annu. Rev. Genomics Hum. Genet., 2: 41-68, 2001.
42. de Boer, J., and Hoeijmakers, J. H. Nucleotide excision repair and human syndromes. Carcinogenesis (Lond.), 21: 453-460, 2000.
43. Kraemer, K. H., Andrews, A. D., Barrett, S. F., and Robbins, J. H. Colony-forming ability of ultraviolet-irradiated xeroderma pigmentosum fibroblasts from different DNA repair complementation groups. Biochim. Biophys. Acta, 442: 147-153, 1976.
44. Andrews, A. D., Barrett, S. F., Yoder, F. W., and Robbins, J. H. Cockayne's syndrome fibroblasts have increased sensitivity to ultraviolet light but normal rates of unscheduled DNA synthesis. J. Investig. Dermatol. 70: 237-239, 1978.
45. Andrews, A. D., Barrett, S. F., and Robbins, J. H. Xeroderma pigmentosum neurological abnormalities correlate with colony-forming ability after ultraviolet radiation. Proc. Natl. Acad. Sci. USA, 75: 1984-1988, 1978.
46. Smith, M. L., Ford, J. M., Hollander, M. C., Bortnick, R. A., Amundson S. A., Seo, Y. R., Deng, C. X., Hanawalt, P. C., and Fornace, A. J., Jr. p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes. Mol. Cell. Biol., 20: 3705-3714, 2000.
47. Hanawalt, P. C. Controlling the efficiency of excision repair. Mutat. Res., 485: 3-13, 2001.
48. Abrahams, P. J., Schouten, R., van Laar, T., Houweling, A., Terleth, C., and van der Eb, A. J. Different regulation of p53 stability in UV-irradiated normal and DNA repair deficient human cells. Mutat. Res., 336: 169-180, 1995.
49. Dumaz, N., Drougard, C., Quilliet, X., Mezzina, M., Sarasin, A., and Daya-Grosjean, L. Recovery of the normal p53 response after UV treatment in DNA repair-deficient fibroblasts by retroviral-mediated correction with the XPD gene. Carcinogenesis (Lond.), 19: 1701-1704, 1998.
50. Ford, J. M., and Hanawalt, P. C. Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. J. Biol. Chem., 272: 28073-80, 1997.
51. Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraishi, K., Fukuda, S., Matsui, K., Takei, Y., and Nakamura, Y. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature (Lond.), 404: 42-49, 2000.
52. Lozano, G., and Elledge, S. J. p53 sends nucleotides to repair DNA. Nature (Lond.), 404: 24-25, 2000.
53. Wang X. W., Vermeulen, W., Coursen, J. D., Gibson, M., Lupold, S. E., Forrester, K., Xu, G., Elmore, L., Yeh, H., Hoeijmakers, J. H., and Harris, C. C. The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. Genes Dev., 10: 1219-1232, 1996.
54. Vogelstein, B., Lane, D., and Levine, A. J. Surfing the p53 network. Nature (Lond.), 408: 307-310, 2000.
55. Burns, T. F., and El-Deiry, W. S. The p53 pathway and apoptosis. J. Cell. Physiol., 181: 231-239, 1999.
56. Kapoor, M., Hamm, R., Yan, W., Taya, Y., and Lozano, G. Cooperative phosphorylation at multiple sites is required to activate p53 in response to UV radiation. Oncogene, 19: 358-364, 2000.
57. Ashcroft, M., and Vousden, K. H. Regulation of p53 stability. Oncogene, 18: 7637-7643, 1999.
58. Tibbetts, R. S., Brumbaugh, K. M., Williams, J. M., Sarkaria, J. N., Cliby, W. A., Shieh, S. Y., Taya, Y., Prives, C., and Abraham, R. T. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev., 13: 152-157, 1999.
59. Lees-Miller, S. P., Sakaguchi, K., Ullrich, S. J., Appella, E., and Anderson, C. W. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. Mol. Cell. Biol., 12: 5041-5049, 1992.
60. O'Brien, S. M., Kantarjian, H. M. Cortes, J. Beran, M., Koller, C. A., Giles, F. J., Lerner, S., and Keating, M. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J. Clin. Oncol., 19: 1414-1420, 2001.
61. Hallek, M., Schmitt, B., Wilhelm, M., Busch, R., Krober, A., Fostitsch, H. P., Sezer, O., Herold, M., Knauf, W., Wendtner, C. M., Kuse, R., Freund, M., Franke, A., Schriever, F., Nerl, C., Dohner, H., Thiel, E., Hiddemann, W., Brittinger, G., Emmerich, B., and German Chronic Lymphocytic Leukaemia Study Group. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a Phase II study of the German CLL Study Group. Br. J. Haematol., 114: 342-348, 2001.
62. Rao V. A., Plunkett W. Nucleoside analog incorporation into repairing DNA kills quiescent cells by an ATM-independent, p53-dependent mechanism. Proc. Am. Assoc. Cancer Res., 43: 797, 2002.